Care in the FinalPhase Fortunately, with present-day treatment methods the duration of the final phase of serious illness has been considerably curtailed and domiciliary nursing care is available throughout the United Kingdom. Also, there are special homes where patients can be treated and nursed in addition to available hospital beds. Much suffering can be assuaged with our skills and drugs, and patients appreciate the personal care and visits of the surgeon who performed their operations. Research continues into pain relief, the treatment of incontinence by electronic devices and the reason for the immunological breakdown.
Progress in Other Directions
Other areas where the surgical oncologist has interests and a contribution to make include prevention, which is of profound importance. Education programmes are required to advise the public to take specific actions. Collaborative research into human oncological problems should be expanded at laboratory and clinical levels and linkages strengthened between hospitals and laboratories so that human oncological problems can be thoroughly investigated. For example, this collaboration is urgently required to solve breast carcinoma problems. The compilation and computer analysis of clinical data on a national scale would yield valuable results regarding epidemiology, symptomatology and prognosis. There is a real need for a closer association of clinical and research oncologists; I believe a research department cannot function to its maximum efficiency in isolation from hospitals where patients are seen and treated.
Terminology
The term 'cancer' has been used for centuries, exercising its depressing influence. I believe it should be discarded as scientifically meaningless and fear-producing. We are dealing with many different diseases, including numerous solid tumours, reticuloses, blood diseases and others, which I feel should now be grouped under the general term 'oncological diseases'. This substitution would remove much fear engendered by the word 'cancer'. The terms medical and surgical oncology have already been accepted. There is a need for oncological terminology in the compilation ofcase-records for computer analysis, and precise terms are required for various operations. This also applies to radiotherapy afthough the term 'deep ray therapy' is disappearing, but 'cobalt therapy' is loosely used. Meaningful terminology is also necessary for chemotherapy where terms such as 'pulse therapy' and 'quadruple therapy' have crept in. The immunotherapist still has time to develop his particular terminology. In this kind of progress opportunity is required for discussion to achieve national and international agreement. I recall our discussions when the name of The Cancer Hospital was changed to The Royal Cancer Hospital, and finally, to The Royal Marsden Hospital which I think was the right decision to help apprehensive patients. Raven Carcinogens in the Environment Of the three main environmental agents that can induce cancer in animals, radiation and chemicals are known with certainty to cause cancer in man. There is still no firm proof that any form of human cancer is caused by a virus but there is increasing evidence that some, particularly lymphoreticular tumours, may be so induced. The amount of human cancer caused by chemicals is not known; however, Boyland (1969) has suggested that not more than 10% of human tumours are caused by radiation or viruses, leaving the remainder, about 90%, attributable to exogenous or endogenous chemicals.
In contrast with the very large number of different chemicals known to cause cancer in experimental animals, there are relatively few for which there is really convincing evidence for carcinogenic activity in man. Hueper (1971) drew up a list of recognized human carcinogens which included asbestos, arsenic, chromium and nickel, benzene and some aromatic amines, coal, tar, pitch, soot, various fuel and lubricating oils, mustard gas and two parasites, Schistosoma ha?matobium, associated with bladder cancer, and Clonarchis sinensis, associated with tumours of the intrahepatic bile ducts. Since then some further highly alarming examples of probable human carcinogens have been reported. It now seems very probable that diethylstilboestrol or related compounds, used in the treatment of threatened abortion and other complications of pregnancy, were responsible for many of the recently described cases of clear-cell adenocarcinoma of the vagina in adolescent girls (Herbst et al. 1971) . Carcinoma of the liver has been associated with prior treatment with anabolic steroids (Johnson et al. 1972 ) and more recently several cases of benign hepatoma have been reported in women taking oral contraceptive steroids (Baum et al. 1973) . Most recent of all, 19 cases of angiosarcoma of the liver have been observed in workers manufacturing polyvinyl chloride (Lee & Hany 1974) . In this case the responsible agent is probably the monomer, vinyl chloride. It is very significant that all four of these human tumours are very rare in Western countries and were thus conspicuous in small numbers. If newly introduced environmental factors are currently causing increases in the incidence of the more common human tumours, the causal relationship will be much more difficult to detect.
The number of chemicals reported to be carcinogenic in animals is enormous and constantly increasing. It includes naturally occurring as well as synthetic compounds. The best known chemical carcinogens include polycyclic aromatic hydrocarbons, aromatic amines, azo dyes, alkylating agents, nitroso compounds, nitroquinoline-N-oxide, urethane nitrofurans and ethionine. The natural carcinogens include fungal products, such as the highly potent aflatoxins, sterigmatocystin and griseofulvin, plant products including pyrrolizidine alkaloids, cycasin, safrole and the carcinogenic component of bracken.
It seems clear, therefore, that there are many known or potential human carcinogens and that their removal or elimination from the environment could result in a greatly decreased incidence of human cancer. An obvious example is the marked reduction in human lung cancer that follows giving up cigarette smoking (Royal College of Physicians 1971).
It is obviously highly desirable that the carcinogenicity of environmental chemicals should be detected before they can cause cancer in human beings and a major trend of oncological research on environmental carcinogens in the next decade should be towards the achievement of this goal. This will require improvement in methods of carcinogenicity testing and in the extrapolation of the results of such tests to man. Since it may be impossible to eliminate a carcinogen completely from the environment, better methods for the assessment of cancer risk to man from low levels of environmental carcinogens are also required.
Only a very small proportion of the components of the chemical environment have been tested in any way for carcinogenic potential and the number of compounds is constantly being increased by the output of the chemical industry. Conventional tests for carcinogenicity have been well worked out and are widely accepted. Since these tests usually require life-time exposure of two animal species to the chemical under test, with detailed pathological examination, they often take more than three years to complete and are very expensive. Clearly an urgent requirement for future research is improvement in methods of assigning priorities for full-scale carcinogenicity testing. Some guidance can be obtained from comparison of the chemical structure of the compound with that of known carcinogens. Further predictive information may be obtained if the compound shows certain specific biological effects such as damage to rapidly growing tissues and effects on mitosis. Even with the best available ranking of priorities, however, there will certainly be more chemicals to be tested than can be accommodated by the available resources for life-time studies. The need for reliable screening tests is therefore imperative.
It is now recognized that most chemical carcinogens are not themselves biologically active but require metabolic conversion in the body into the true carcinogenic products, usually by the mixed-function oxidases of the microsomal fraction of the liver and other organs. These reactive so-called ultimate carcinogens have proved, apparently without exception, to be mutagenic, when tested in appropriate systems (Miller & Miller 1966 , 1971 , Ames et al. 1973 ). The implication of this generalization is that tests for mutagenic activity may give valuable pointers to carcinogenic activity.
The induction of malignant transformation of cells cultured in vitro is now well established and the recent achievement of cultures of liver parenchymal cells in several laboratories may be developed to provide reliable systems for the detection of carcinogenicity. Considerable advances are also being made in the use of liver microsomal enzyme systems for conversion of chemicals to active products that can be scored for mutagenicity in microbial systems (Ames et a!. 1973) , and similar procedures are being developed for use with mammalian, including human, cells in vitro.
Little information is available on the nature of the dose-response curve for chemical carcinogens at the very low levels at which some of them are now detectable in the environment. Attemots to solve this problem, involving the use of very large numbers of rodents, are currentlv in progress. These experiments present formidable problems in planning, execution and interpreta-743 tion. Increased knowledge of the defence mechanisms of the body against chemical carcinogenesis is highly desirable.
Professor A Munro Neville (Division ofPathology, Institute ofCancer Research: Royal Cancer Hospital, Chester Beatty Research Institute, Fulham Road, London SW3 6JB)
The Early Detection of Cancer The early recognition of tumours, while still truly localized and amenable to curative therapy, represents a major challenge to oncologists as it did 2000 years ago when Celsus first discussed the subject and noted that 'only the beginning of cancer permits its cure'. In this context, it is important to distinguish between the earlier detection of tumours and the detection of earlier tumours, i.e. earlier in their life history.
Early diagnosis has been defined as the detection of tumours prior to their causing symptoms or becoming palpable. However, even such tumours would appear to have been present for many years before; by the time a tumour is 1 cm in size three-quarters of its total life span has already passed (Collins et al. 1956 ). Moreover, observations of the growth rate of metastases indicate that they may be established and have commenced growing well before the earliest sign or symptom drew clinical attention to the primary tumour (Collins et al. 1956 , Bruce et al. 1970 , Galasko 1972 .
Consequently, so-called early diagnosis is not necessarily equatable with an early growth and enhanced survival. The important question is not that small seemingly localized tumours are associated with a better prognosis than larger growths (Easson & Russell 1968 ), but why some tumours, while small, remain localized and others of similar size will have metastasized.
Accurate staging of tumours at the time of initial treatment is also a prerequisite for which methods of earlier discovery of metastases are needed. It has been largely through detailed knowledge of the extent of disease that improved therapeutic schedules have been designed and better results attained in many tumours, including choriocarcinoma (Bagshawe 1969) and Hodgkin's disease (Fairley 1973) .
A wide range of physical methods is available or under study to supplement clinical examination in facilitating tumour detection. They include endoscopy, exfoliative cytology, radiology and its more specialized applications such as mammography and xeroradiography, radioisotopes and ultrasonography. Many 'screening programmes' have been built round the use of one or more of these techniques. Unfortunately, they have the disadvantages of being site-orientated rather than of general use and the size of the detectable lesion is a critical factor for many of them.
Consequently, it is not surprising that the zeal of many scientists has been directed towards evolving a test or tests of universal application irrespective of tumour size or site. Many have been proposed; none has yet been proved to possess adequate specificity or sensitivity.
The recent evidence that human tumours may express distinct neoantigens, which can influence the host's immunological system and/or which may be released from the tumour and detected in the biological fluids, has provided a new approach to cancer diagnosis. While tumour-specific antibodies have been demonstrated in the sera of patients with a wide variety of tumours, most interest related to improved diagnosis has centred around studies ofcell-mediated immune reactions. The present evidence would seem to suggest that human tumours of similar origin and histogenesis possess common cross-reacting tumourassociated antigens (Hellstrom & Hellstrom 1972) .
Field & Caspary (1971) have developed a macrophage electrophoretic mobility (MEM) test which is considered to be a sensitive and qualitative in vitro method of assessing cellmediated immune function. Using the encephalitogenic factor or a basic extract of human malignant tumours (cancer basic protein) as antigen(s), positive results were observed with lymphocytes from cancer-bearing subjects, but not from controls or patients with benign disease. All malignant tumours, irrespective of site, stage or histology, gave positive results which persisted after apparent complete surgical cure. The anticipatory nature of the test is shown by the positive results obtained in subjects with in-situ cervical carcinoma and up to eight and eleven years before the clinical overt appearance of a mammary and thyroid carcinoma respectively. Although suf-
